Rajiv Khosla

Dr. Rajiv Khosla currently serves as Enteris BioPharma’s Chief Executive Officer. He joined the Company in April 2020, bringing more than 30 years of biopharmaceutical industry experience as both a consultant and senior corporate executive to the company. As CEO, Dr. Khosla is leading Enteris as the company targets multiple growth opportunities built around Peptelligence®, the company’s proprietary oral peptide and small molecule drug delivery platform.

During Dr. Khosla’s three-decade career in the biopharmaceutical industry, he has demonstrated an ability to successfully apply his expertise at multiple companies, spanning early-stage to established industry leaders. In 2011, Dr. Khosla founded CEUTEC LLC, a strategy and business development consultancy serving biopharmaceutical companies and venture capital firms. In that capacity, Dr. Khosla consulted with a variety of biopharmaceutical, drug delivery, and medical device companies to implement business strategies, 505(b)(2) product pipeline programs leading to successful FDA filings, and licensing transactions.

Prior to CEUTEC, Dr. Khosla held several senior roles in large and small biopharmaceutical companies, most recently at the former Biovail Corp. as Vice President of Business Development. Dr. Khosla has served on the Boards of Orasi Medical, IntelGenx, and BioNJ. Dr. Khosla received a Bachelor of Pharmacy with honors and a Ph.D. in Pharmaceutical Drug Delivery from the University of Nottingham in England. He earned an Executive M.B.A. from the Henley Business School at the University of Reading. Dr. Khosla is a member of the Royal Pharmaceutical Society of Great Britain.